Pharmacold will become a subsidiary of Holm & Halby, a company within AddLife’s business Area Labtech. The company brings extensive experience in managing critical and highly customised installations for the pharmaceutical and research sectors, where stable operation and documented quality are essential. Pharmacold, with a current revenue of EUR 3.4 million, operates primarily in Denmark.

“The acquisition of Pharmacold, together with Holm & Halby’s Cold Storage division, enables us to offer a broader and more comprehensive product portfolio. Holm & Halby’s extensive customer network and deep expertise in quality and regulatory matters also present significant opportunities for Pharmacold’s future growth. We look forward to further developing our product and service offerings and strengthening our market position in Denmark,” says Mattias Bengtsson, Vice President Biomedical and Research, AddLife.

Opitek wil become part of Mediplast

Opitek International will become part of Mediplast, a company within AddLife’s Business Area Medtech. The Danish medtech company is renowned for its specialized solutions in safe and efficient patient positioning before and during surgery, with sales of approximately DKK 8 million.

“We are delighted to welcome Opitek to the Mediplast Group. Opitek’s innovative solutions for patient positioning are highly complementary to our existing portfolio and will further strengthen our offering in the rapidly growing orthopedic field. This acquisition is aligned with our strategy to expand our own brands and leverage the AddLife platform for accelerated growth. By combining Opitek’s expertise and established customer relationships with our resources and market presence, we are confident that we will deliver enhanced value to our customers and drive long-term profitable growth for the Group,” says Johan Bongstorp, CEO Mediplast Group.